Jim Simons Xilio Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 164,200 shares of XLO stock, worth $114,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares

164,200

Previous 177,700 7.6%

Holding current value

$114,939

Previous $127,000 12.6%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$0.65 - $1.15 $8,775 - $15,524	-13,500 Reduced 7.6%	164,200 $111,000
Q1 2025 May 14, 2025	SELL	$0.65 - $1.48 $77,296 - $175,997	-118,917 Reduced 40.09%	177,700 $127,000
Q4 2024 Feb 13, 2025	BUY	$0.75 - $1.44 $22,737 - $43,656	30,317 Added 11.38%	296,617 $284,000
Q3 2024 Nov 13, 2024	SELL	$0.73 - $1.02 $20,951 - $29,274	-28,700 Reduced 9.73%	266,300 $210,000
Q2 2024 Aug 09, 2024	BUY	$0.9 - $1.53 $40,998 - $69,697	45,554 Added 18.26%	295,000 $280,000
Q1 2024 May 13, 2024	BUY	$0.55 - $1.08 $21,860 - $42,925	39,746 Added 18.95%	249,446 $269,000
Q4 2023 Feb 13, 2024	BUY	$0.5 - $2.5 $94,500 - $472,500	189,000 Added 913.04%	209,700 $115,000
Q3 2023 Nov 14, 2023	BUY	$2.11 - $2.9 $844 - $1,160	400 Added 1.97%	20,700 $44,000
Q2 2023 Aug 11, 2023	BUY	$2.55 - $3.46 $3,824 - $5,190	1,500 Added 7.98%	20,300 $53,000
Q1 2023 May 12, 2023	SELL	$2.66 - $4.28 $48,678 - $78,324	-18,300 Reduced 49.33%	18,800 $60,000
Q4 2022 Feb 13, 2023	BUY	$1.97 - $3.03 $16,942 - $26,058	8,600 Added 30.18%	37,100 $100,000
Q3 2022 Nov 14, 2022	SELL	$2.07 - $3.44 $96,875 - $160,992	-46,800 Reduced 62.15%	28,500 $83,000
Q2 2022 Aug 12, 2022	BUY	$2.08 - $7.2 $156,624 - $542,160	75,300 New	75,300 $220,000

Others Institutions Holding XLO

# of Institutions

Shares Held

12.5M

Call Options Held

Put Options Held

View Full List

About Xilio Therapeutics, Inc.

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $19.2M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

More about XLO

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account